Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-label Study to Assess the Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Patients with Metastatic Advanced Stage Ovarian Cancer

Next Previous
Trial Profile

A Phase 2 Open-label Study to Assess the Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Patients with Metastatic Advanced Stage Ovarian Cancer

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; HCW 9218 (Primary) ; Paclitaxel (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

Most Recent Events

  • 11 Oct 2024 Status changed from recruiting to withdrawn prior to enrolment.
  • 25 May 2024 Drug Bintrafusp alfa (M7824) has been removed and drug HCW9218 has added to study protocol. Study phase changed from 1 to 2. Company HCW Biologics updated as Collaborators. Primary and secondary outcome measures amended. Exclusion criteria amended. PD is also a trial focus now.
  • 25 May 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top